SARS-CoV-2 and Mycobacterium Fortuitum Coinfection: A Case Report

Year 2025, Volume: 78 Issue: 2, 157 - 160, 01.07.2025

Ezgi Gülten , Gültaze Gül , Hatice Maraş , Özgür Demir , Güle Çınar , Elif Mukime Sarıcaoğlu , Ebru Uslu , Mehmet Serhat Birengel

Abstract

Coronavirus disease-2019 (COVID-19) pandemic caused millions of people to become infected and had resulted several deaths. After initial resolution, in cases of clinical deterioration, it is essential to consider the possibility of coinfections. Non-tuberculous mycobacteria infections are rare and often overlooked. In this report, we present a severe acute respiratory syndrome-Coronavirus-2 and Mycobacterium fortuitum coinfected patient. Our intention is to bring attention to the possibility of such coinfection without a known history of any lung diseases or immunosuppression other than COVID-19 and thus, broadening the clinical thinking process of physicians

Keywords

SARS-CoV-2 , non-tuberculous mycobacteria , COVID-19

SARS-CoV-2 ve Mycobacterium Fortuitum Koenfeksiyonu: Olgu Sunumu

Abstract

Koronavirüs hastalığı-2019 (COVID-19) pandemisi milyonlarca insanın enfekte olmasına ve çok sayıda ölüme neden olmuştur. Başlangıçtaki iyileşme döneminin ardından klinik kötüleşme olması halinde koenfeksiyon olasılığını düşünmek gerekmektedir. Tüberküloz dışı mikobakteri enfeksiyonları nadir olup sıklıkla gözden kaçırılmaktadır. Bu yazıda şiddetli akut solunum sendromu-Koronavirüs-2 ve Mycobacterium fortuitum koenfeksiyonu olan bir hasta sunmaktayız. Amacımız, eşlik eden akciğer hastalığı ve COVID-19 dışında immünosüpresyon öyküsü bulunmadığında da bu koenfeksiyonun gelişebileceğine dikkat çekmek ve hekimlerin klinik yaklaşımına katkı sağlamaktır

Keywords

SARS-CoV-2 , tüberküloz dışı mikobakteri , COVID-19

Ethical Statement

Informed Consent: Consent was obtained from the patient and his relative.

References

• 1. Griffith DE, Aksamit T, Brown-Elliott BA, et al. ATS mycobacterial diseases subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416.
• 2. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535.
• 3. Lange C, Böttger EC, Cambau E, et al. Expert panel group for management recommendations in non-tuberculous mycobacterial pulmonary diseases. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022;22:e178-e190. 160
• 4. Wu HY, Chang PH, Chen KY, et al. GREAT working group. Coronavirus disease 2019 (COVID-19) associated bacterial coinfection: incidence, diagnosis and treatment. J Microbiol Immunol Infect. 2022;55:985-992.
• 5. Rodriguez JA, Bonnano C, Khatiwada P, et al. COVID-19 coinfection with Mycobacterium abscessus in a patient with multiple myyeloma. Case Rep Infect Dis. 2021;2021:8840536.
• 6. Tsai YC, Huang WC, Mao YC, et al. Mycobacterium fortuitum infection from needlefish impalement during diving: a diagnostic challenge. Travel Med Infect Dis. 2021;41:102056.
• 7. Singh Bhalla G, Grover N, Singh G, et al. Prevalence of non tuberculous mycobacterial infection in surgical site infections and their antibiotic susceptibility profile. Med J Armed Forces India. 2021;77:343-348.
• 8. Yeap KC, Sivagurunathan PD, Raman P, et al. Non-tuberculous mycobacterial ocular infection masquerading as choroidal tumour - a diagnostic conundrum. GMS Ophthalmol Cases. 2019;9:Doc25.
• 9. Cong J, Wang C, Ma L, et al. Septicemia and pneumonia due to Mycobacterium fortuitum infection in a patient with extronodal NK/T-cell lymphoma, nasal type: a case report. Medicine (Baltimore). 2017;96:e6800.
• 10. d’Incau S, Vargas MI, Calmy A, et al. Mycobaterium fortuitum disseminated infection in an immunocompetent patient without predisposing factors. BMJ Case Rep. 2020;13:e235842.
• 11. Dahl VN, Mølhave M, Fløe A, et al. Global trends of pulmonary infections with non-tuberculous Mycobacteria: a systematic review. Int J Infect Dis. 2022;125:120-131.
• 12. Kodana M, Tarumoto N, Kawamura T, et al. Utility of the MALDITOF MS method to identify non-tuberculous mycobacteria. J Infect Chemother. 2016;22:32-35.
• 13. CLSI. Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. 2nd Edition. CLSI supplement M24S. Clinical and Laboratory Standards Institute; 2023.
• 14. Siddique N, Roy M, Ahmad S. Mycobacterium fortuitum abscess following breast nipple piercing. IDCases. 202021:e00847.